

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Termination of Assignment of Security Interest in United States Trademarks

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
The CIT Group/Business Credit, Inc., as Collateral Agent		08/20/2007	CORPORATION:

RECEIVING PARTY DATA

Name:	Oncology Therapeutics Network Corporation
Street Address:	395 Oyster Point Boulevard, Suite 500
City:	South San Francisco
State/Country:	CALIFORNIA
Postal Code:	94080
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
Registration Number:	2436807	LYNX
Registration Number:	2188494	LYNX
Registration Number:	2514160	LYNX FROM OTN
Registration Number:	2834500	LYNX2OTN
Registration Number:	2834501	LYNX2OTN
Registration Number:	1693636	ONCOLOGY THERAPEUTICS NETWORK
Registration Number:	1692365	ONCOLOGY THERAPEUTICS NETWORK
Serial Number:	75923578	ORCA
Registration Number:	2766749	OTN ONCOLOGY THERAPEUTICS NETWORK
Registration Number:	2435029	
Serial Number:	78385621	ZIP KIT

CORRESPONDENCE DATA

Fax Number: (213)996-3339

900085130

**TRADEMARK
 REEL: 003607 FRAME: 0281**

OP \$290.00 2436807

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 2136836339
Email: claudiaimmerzeel@paulhastings.com
Correspondent Name: Paul Hastings Janofsky & Walker LLP
Address Line 1: 515 South Flower Street, 25th Floor
Address Line 4: Los Angeles, CALIFORNIA 90071

ATTORNEY DOCKET NUMBER:	45035.00252
NAME OF SUBMITTER:	Claudia R Immerzeel
Signature:	/Claudia R Immerzeel/
Date:	08/22/2007

Total Attachments: 4
source=OTNTerminationTM#page1.tif
source=OTNTerminationTM#page2.tif
source=OTNTerminationTM#page3.tif
source=OTNTerminationTM#page4.tif

**TERMINATION OF ASSIGNMENT OF SECURITY INTEREST IN UNITED STATES
TRADEMARKS**

This TERMINATION OF ASSIGNMENT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS is executed as of August 20, 2007 by The CIT Group/Business Credit, Inc. (the "Collateral Agent"), with reference to that certain Financing Agreement dated as of May 11, 2005 (as amended, supplemented or otherwise modified, the "Financing Agreement") among Oncology Therapeutics Network Joint Venture, L.P., as the Borrower, OTN Generics, Inc. and Onmark, Inc. as Co-Borrowers, Oncology Holdings, Inc., as a Guarantor, the financial institutions from time to time party thereto, as lenders and The CIT Group/Business Credit, Inc., a New York corporation, as the administrative and collateral agent for the Lenders.

WHEREAS, pursuant to the Financing Agreement, Oncology Therapeutics Network Corporation, a Delaware corporation (the "Assignor"), executed and delivered to the Collateral Agent, for the benefit of the Lenders, that certain Assignment of Security Interest in United States Trademarks, dated as of May 11, 2005 (as the same may have been amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Assignment"; capitalized terms used herein without definition have the meanings provided in the Assignment (or if not provided therein, in the Financing Agreement)), pursuant to which Assignment the Assignor has granted and pledged to the Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of the Assignor's right, title and interest in, to and under all Trademarks and Trademark Licenses and various products or proceeds thereof (collectively, the "Trademark Collateral"), all as more fully set forth in the Assignment;

WHEREAS, the Assignment was recorded with the United States Patent & Trademark Office on June 2, 2005 at Reel 3125, Frame 0925; and

WHEREAS, the Financing Agreement is being terminated, and in connection therewith, the Collateral Agent has agreed to release its security interests in all of the Trademark Collateral.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Collateral Agent hereby:

A. releases the liens and security interests granted by the Assignor to the Collateral Agents in any Trademark Collateral pursuant to any security agreement (including but not limited to the Assignment), including without limitation each item of Trademark Collateral listed on Schedule I hereto;

B. to the extent the Collateral Agent shall be deemed to have any right, title or interest in, to and under any item of Trademark Collateral held by the Assignor, the Collateral Agent hereby retransfers and reassigns to the Assignor all of such right, title and interest with respect to any such item of Trademark Collateral, including without limitation each item of Trademark Collateral listed on Schedule I hereto; and


C. terminates the Assignment.

THIS TERMINATION OF ASSIGNMENT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (WITHOUT REFERENCE TO CONFLICT OF LAWS PRINCIPLES BUT INCLUDING AND GIVING EFFECT TO SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW).

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the undersigned has caused this Termination of Assignment of Security Interest in United States Trademarks to be executed by its duly authorized officer as of the date first written above.

**THE CIT GROUP/BUSINESS CREDIT,
INC.**
as Collateral Agent

By 
Name: John Finora
Title: Vice President

SCHEDULE I
TRADEMARKS
AND TRADEMARK LICENSES

TRADEMARKS

<u>Country</u>	<u>Mark</u>	<u>Reg. / App. No.</u>	<u>Reg. / App. Date</u>	<u>Class(es)</u>
U.S.A.	LYNX	2,436,807	3/20/2001	42
U.S.A.	LYNX	2,188,494	4/8/2005	9
U.S.A.	LYNX Design	2,514,160	12/4/2001	42
U.S.A.	LYNX2OTN	2,834,500	4/20/2004	44
U.S.A.	LYNX2OTN & Design	2,834,501	4/20/2004	44
U.S.A.	ONCOLOGY THERAPEUTICS NETWORK	1,693,636	6/9/1992	42
U.S.A.	ONCOLOGY THERAPEUTICS NETWORK	1,692,365	6/9/1992	5
U.S.A.	ORCA	75/923578	2/19/2000	35
U.S.A.	OTN LOGO	2,766,749	9/23/2003	35
U.S.A.	Paw Print Design	2,435,029	3/13/2001	35
U.S.A.	ZIP KIT	78/385621	3/17/2004	10